Clinical trial
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating…
NCT00227669 · UNICANCER, Other · Completed
Key facts
| NCT number | NCT00227669 |
|---|---|
| Title | Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma |
| Official title | Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas |
| Lead sponsor | UNICANCER, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | docetaxel, gemcitabine hydrochloride |
| Enrollment | 90 |
| Start date | Oct 1, 2005 |
| Primary completion | Feb 1, 2010 |
| Completion | Aug 1, 2012 |
| First posted | Sep 28, 2005 |
| Last update posted | Aug 30, 2016 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: